Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377019899> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4377019899 endingPage "388" @default.
- W4377019899 startingPage "383" @default.
- W4377019899 abstract "Though melanoma is one of the less common skin malignancies, it accounts for the majority of deaths due to cutaneous cancers. The recent progress and drug approvals in targeted treatment and immunotherapy revolutionized the outcome of patients with metastatic disease, and now is also changing the landscape of adjuvant treatment in melanoma.A combination of anti-PD-1 and anti-CTLA-4 (nivolumab with ipilimumab) has demonstrated superior outcomes in terms of progression-free survival (PFS) and overall survival with recent data confirming median survival exceeding six years. However, the use of this immunotherapy combination is limited in routine practice to approximately half of the patients due to high toxicity with the majority of patients at risk of severe adverse events. The current efforts are to determine how best to integrate combination immunotherapy in different clinical scenarios and limit these drugs' toxicity. That is why novel strategies in immunotherapy are needed and one of the examples of such novelty are anti-LAG-3 antibodies (lymphocyte-activation gene 3). LAG-3 inhibitor (relatlimab) in combination with nivolumab significantly improved PFS as compared to anti-PD-1 monotherapy in patients with previously untreated metastatic or unresectable melanoma. We describe the current status of combination of nivolumab+ relatlimab in the treatment of advanced melanoma patients based on the available data coming from pivotal clinical trials.The most important question to be answered is what would be the place of this novel combination in the treatment planning strategy." @default.
- W4377019899 created "2023-05-19" @default.
- W4377019899 creator A5028764652 @default.
- W4377019899 creator A5063245135 @default.
- W4377019899 date "2023-05-04" @default.
- W4377019899 modified "2023-10-11" @default.
- W4377019899 title "Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma" @default.
- W4377019899 cites W1536612607 @default.
- W4377019899 cites W2117443086 @default.
- W4377019899 cites W2128035403 @default.
- W4377019899 cites W2515693796 @default.
- W4377019899 cites W2519279652 @default.
- W4377019899 cites W2747107882 @default.
- W4377019899 cites W2763933536 @default.
- W4377019899 cites W2808814350 @default.
- W4377019899 cites W2894796660 @default.
- W4377019899 cites W2896600825 @default.
- W4377019899 cites W2913383852 @default.
- W4377019899 cites W2915708315 @default.
- W4377019899 cites W2947765148 @default.
- W4377019899 cites W2955181150 @default.
- W4377019899 cites W2963476376 @default.
- W4377019899 cites W3043703771 @default.
- W4377019899 cites W3047382685 @default.
- W4377019899 cites W3090469545 @default.
- W4377019899 cites W3166578944 @default.
- W4377019899 cites W3176956457 @default.
- W4377019899 cites W3217534140 @default.
- W4377019899 cites W4221077502 @default.
- W4377019899 cites W4225394054 @default.
- W4377019899 cites W4225947493 @default.
- W4377019899 cites W4256631179 @default.
- W4377019899 cites W4282022545 @default.
- W4377019899 cites W4286295255 @default.
- W4377019899 cites W4292229910 @default.
- W4377019899 cites W4294100626 @default.
- W4377019899 doi "https://doi.org/10.1080/14712598.2023.2215922" @default.
- W4377019899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37200112" @default.
- W4377019899 hasPublicationYear "2023" @default.
- W4377019899 type Work @default.
- W4377019899 citedByCount "1" @default.
- W4377019899 countsByYear W43770198992023 @default.
- W4377019899 crossrefType "journal-article" @default.
- W4377019899 hasAuthorship W4377019899A5028764652 @default.
- W4377019899 hasAuthorship W4377019899A5063245135 @default.
- W4377019899 hasConcept C121608353 @default.
- W4377019899 hasConcept C126322002 @default.
- W4377019899 hasConcept C143998085 @default.
- W4377019899 hasConcept C197934379 @default.
- W4377019899 hasConcept C2776999253 @default.
- W4377019899 hasConcept C2777658100 @default.
- W4377019899 hasConcept C2777701055 @default.
- W4377019899 hasConcept C2780030458 @default.
- W4377019899 hasConcept C2781433595 @default.
- W4377019899 hasConcept C502942594 @default.
- W4377019899 hasConcept C71924100 @default.
- W4377019899 hasConceptScore W4377019899C121608353 @default.
- W4377019899 hasConceptScore W4377019899C126322002 @default.
- W4377019899 hasConceptScore W4377019899C143998085 @default.
- W4377019899 hasConceptScore W4377019899C197934379 @default.
- W4377019899 hasConceptScore W4377019899C2776999253 @default.
- W4377019899 hasConceptScore W4377019899C2777658100 @default.
- W4377019899 hasConceptScore W4377019899C2777701055 @default.
- W4377019899 hasConceptScore W4377019899C2780030458 @default.
- W4377019899 hasConceptScore W4377019899C2781433595 @default.
- W4377019899 hasConceptScore W4377019899C502942594 @default.
- W4377019899 hasConceptScore W4377019899C71924100 @default.
- W4377019899 hasIssue "5" @default.
- W4377019899 hasLocation W43770198991 @default.
- W4377019899 hasLocation W43770198992 @default.
- W4377019899 hasOpenAccess W4377019899 @default.
- W4377019899 hasPrimaryLocation W43770198991 @default.
- W4377019899 hasRelatedWork W1963731933 @default.
- W4377019899 hasRelatedWork W2225212058 @default.
- W4377019899 hasRelatedWork W2936603379 @default.
- W4377019899 hasRelatedWork W2947988614 @default.
- W4377019899 hasRelatedWork W2955428297 @default.
- W4377019899 hasRelatedWork W3005150264 @default.
- W4377019899 hasRelatedWork W3029766637 @default.
- W4377019899 hasRelatedWork W3094969222 @default.
- W4377019899 hasRelatedWork W3170189973 @default.
- W4377019899 hasRelatedWork W4362587156 @default.
- W4377019899 hasVolume "23" @default.
- W4377019899 isParatext "false" @default.
- W4377019899 isRetracted "false" @default.
- W4377019899 workType "article" @default.